US approves "milestone" Parkinson's treatment for 2025 release
Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease. The US FDA this week approved the sale of the treatment, which harnesses innovative technology to make managing the condition easier and more impactful,
FDA approves Supernus’ Onapgo to treat advanced Parkinson’s disease
The US Food and Drug Administration (FDA) has approved Supernus Pharmaceuticals’ Onapgo (apomorphine hydrochloride) injection to treat motor fluctuations in adults with advanced Parkinson’s disease (PD).
FDA approves wearable infusion device for advanced Parkinson disease
The U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in patients with advanced Parkinson disease,
Supernus' 4th try proves the charm with long-awaited FDA approval for Parkinson's infusion pump Onapgo
Three strikes and you’re out? Not for Supernus Pharmaceuticals and its Parkinson’s disease infusion pump. | The device is meant to allow patients more control over their "off" time, or the instances when medicine wears off and symptoms return or worsen.
Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease
ONAPGOis the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s
FDA approves Onapgo for motor fluctuations in adults with Parkinson’s disease
The FDA has approved Onapgo, the first subcutaneous apomorphine device to treat motor fluctuations in adults with Parkinson’s disease, according to the manufacturer.In a press release, Supernus Pharmaceuticals Inc.
FDA Approves First Subcutaneous Apomorphine Device for Parkinson Disease
The FDA has approved the first and only subcutaneous apomorphine infusion device, apomorphine hydrochloride injection (Onapgo), for the treatment of adults with advanced Parkinson disease.
U.S. FDA approves Supernus' drug-device combination for Parkinson's disease
The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat movement-related symptoms of Parkinson's disease, the drugmaker said on Tuesday. Shares of the company were up 5% in early trading.
Supernus Gets FDA Approval of Onapgo Device for Parkinson's Disease
Supernus Pharmaceuticals has won Food and Drug Administration approval for its Onapgo device to treat patients with Parkinson's disease.
Supernus stock surges on FDA approval
Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) climbed 5.5% Tuesday as the U.S. Food and Drug Administration approved ONAPGO for the treatment of motor fluctuations in adults with advanced Parkinson's disease.
Supernus stock climbs 5% on FDA approval of Onapgo
Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) rose 5% Tuesday morning on news the FDA has approved its wearable treatment device Onapgo, formerly known as SPN-830, for the treatment of patients with Parkinson's disease.
Hosted on MSN20h
Supernus wins FDA approval for Parkinson’s pump on fourth try
Supernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride) to treat symptoms of ...
Supernus: New Approval Holds Promise Of Increased Growth
Supernus Pharmaceuticals' FDA approval for ONAPGO in Parkinson's Disease offers optimism despite past challenges, with a ...
BioSpace2d
Supernus Taps Potential $300M US Opportunity With FDA Win for Parkinson’s Drug-Device Combo
The FDA on Tuesday signed off on Supernus Pharmaceuticals’ apomorphine hydrochloride injection—to be marketed under the brand ...
Stifel maintains hold on Supernus, price target at $38
Stifel analysts maintained their Hold rating on Supernus Pharmaceuticals (NASDAQ:SUPN) shares, with a steady price target of $38.00. Trading near its 52-week high with a strong 30% gain over the past ...